November 3rd, 2014
Selections from Richard Lehman’s Literature Review: November 3rd
Richard Lehman, BM, BCh, MRCGP
This week’s topics include dual-antiplatelet treatment beyond one year after DES implantation, reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome, and more.
January 18th, 2012
Cangrelor and Alaska’s “Bridge to Nowhere”
Richard A. Lange, MD, MBA and L. David Hillis, MD
The Gravina Island Bridge (also known as The Bridge to Nowhere) was a proposed bridge to replace the ferry that currently connects Ketchikan, Alaska (population, 14,000) to the Ketchikan International Airport on Gravina Island (population, 50) at a projected cost of $398 million. The bridge was to have been nearly as long as the Golden Gate […]
January 17th, 2012
Cangrelor Proposed as Bridge to Surgery
Larry Husten, PHD
As a potent and reversible platelet inhibitor, cangrelor has been proposed for use in a bridging strategy for patients scheduled for surgery who are currently taking clopidogrel or another thienopyridine. To test this strategy, the BRIDGE investigators randomized 210 ACS or stent patients awaiting CABG and taking a thienopyridine to receive either cangrelor or placebo for at […]
NEJM Journal Watch — Recent Cardiology Articles- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy